Advertisement
Screener

Cingulate Inc. (CING) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

2.8 / 5 stars · 68/120 Roast Me

Cingulate Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Cingulate Inc. (CING) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $1.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-08-13

  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2026-06-30 was $1.36M, a 9.13% increase year-over-year.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2026-03-31 was $2.09M, a 110.95% increase year-over-year.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2025-12-31 was $1.32M, a 1.39% increase year-over-year.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2025-09-30 was $1.23M, a 32.99% decline year-over-year.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $4.79M, a 0.35% decline from fiscal 2024.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $4.80M, a 31.89% decline from fiscal 2023.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $7.05M, a 48.95% increase from fiscal 2022.
  • Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $4.73M, a 563.21% increase from fiscal 2021.
Period endEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 3 monthEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 3 month as first filedEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 monthEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 month as first filedEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 9 monthEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 9 month as first filedEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month
2026-06-30$1.36M
10-Q · filed 2026-08-13
$3.45M
10-Q · filed 2026-08-13
$4.77M
derived: sum of 3 quarters · filed 2026-08-13
$6.00M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$2.09M
10-Q · filed 2026-05-14
$3.41M
derived: sum of 2 quarters · filed 2026-05-14
$4.64M
derived: sum of 3 quarters · filed 2026-05-14
$5.88M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$1.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$2.55M
derived: sum of 2 quarters · filed 2026-03-18
$3.80M
derived: sum of 3 quarters · filed 2026-08-13
$4.79M
10-K · filed 2026-03-18
2025-09-30$1.23M
10-Q · filed 2025-11-13
$2.47M
derived: sum of 2 quarters · filed 2026-08-13
$3.46M
10-Q · filed 2025-11-13
$4.77M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$1.25M
10-Q · filed 2026-08-13
$2.24M
10-Q · filed 2026-08-13
$3.54M
derived: sum of 3 quarters · filed 2026-08-13
$5.37M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$989.99K
10-Q · filed 2026-05-14
$2.29M
derived: sum of 2 quarters · filed 2026-05-14
$4.12M
derived: sum of 3 quarters · filed 2026-05-14
$5.02M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$1.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$3.13M
derived: sum of 2 quarters · filed 2026-03-18
$4.03M
derived: sum of 3 quarters · filed 2026-03-18
$4.80M
10-K · filed 2026-03-18
2024-09-30$1.83M
10-Q · filed 2025-11-13
$2.73M
derived: sum of 2 quarters · filed 2025-11-13
$3.50M
10-Q · filed 2025-11-13
$5.46M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$897.44K
10-Q · filed 2025-08-19
$1.67M
10-Q · filed 2025-08-19
$3.63M
derived: sum of 3 quarters · filed 2025-08-19
$5.85M
derived: sum of 4 quarters · filed 2025-08-19
2024-03-31$770.44K
10-Q · filed 2025-05-08
$2.73M
derived: sum of 2 quarters · filed 2025-05-08
$4.95M
derived: sum of 3 quarters · filed 2025-05-08
$6.74M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$1.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$4.18M
derived: sum of 2 quarters · filed 2025-03-27
$5.97M
derived: sum of 3 quarters · filed 2025-03-27
$7.05M
10-K · filed 2025-03-27
2023-09-30$2.22M
10-Q · filed 2024-11-07
$4.00M
derived: sum of 2 quarters · filed 2024-11-07
$5.09M
10-Q · filed 2024-11-07
$6.26M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$1.79M
10-Q · filed 2024-08-13
$1.78M
10-Q · filed 2023-08-14
$2.88M
10-Q · filed 2024-08-13
$2.87M
10-Q · filed 2023-08-14
$4.04M
derived: sum of 3 quarters · filed 2024-08-13
$5.17M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$1.09M
10-Q · filed 2024-05-08
$2.25M
derived: sum of 2 quarters · filed 2024-05-08
$3.38M
derived: sum of 3 quarters · filed 2024-05-08
$4.46M
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31$1.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$2.29M
derived: sum of 2 quarters · filed 2024-04-01
$3.37M
derived: sum of 3 quarters · filed 2024-04-01
$4.73M
10-K · filed 2024-04-01
2022-09-30$1.13M
10-Q · filed 2023-11-13
$1.25M
10-Q · filed 2022-11-14
$2.21M
derived: sum of 2 quarters · filed 2023-11-13
$3.57M
10-Q · filed 2023-11-13
$3.69M
10-Q · filed 2022-11-14
2022-06-30$1.08M
10-Q · filed 2023-08-14
$2.44M
10-Q · filed 2023-08-14
2022-03-31$1.36M
10-Q · filed 2023-05-10
2021-12-31$713.70K
10-K · filed 2023-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
OS Therapies Inc (OSTX)United States$0.076B-2.17
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
iBio, Inc. (IBIO)United States$0.077B-2.94